Chemomab Therapeutics
Pharmaceuticals, 5900 Ne 152nd Ave, Vancouver, Washington, 98682, United States, 11-50 Employees
Phone Number: +15*********
Who is CHEMOMAB THERAPEUTICS
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal...
Read More
-
Headquarters: 5900 Ne 152nd Ave, Vancouver, Washington, 98682, United States
-
Date Founded: 2011
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 8711
Does something look wrong? Fix it. | View contact records from CHEMOMAB THERAPEUTICS
Chemomab Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Chemomab Therapeutics
Answer: Chemomab Therapeutics's headquarters are located at 5900 Ne 152nd Ave, Vancouver, Washington, 98682, United States
Answer: Chemomab Therapeutics's phone number is +15*********
Answer: Chemomab Therapeutics's official website is https://chemomab.com
Answer: Chemomab Therapeutics's revenue is $5 Million to $10 Million
Answer: Chemomab Therapeutics's SIC: 8711
Answer: Chemomab Therapeutics has 11-50 employees
Answer: Chemomab Therapeutics is in Pharmaceuticals
Answer: Chemomab Therapeutics contact info: Phone number: +15********* Website: https://chemomab.com
Answer: Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe and well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. The company has reported encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month